“BAFF receptor—A novel therapeutic target for B cell malignancies”

The next Case Comprehensive Cancer Center Seminar Series event will be a discussion on “BAFF receptor—A novel therapeutic target for B cell malignancies.”

Reshmi Parameswaran, assistant professor of medicine and member of the Hematopoietic and Immune Cancer Biology Program of the Case Comprehensive Cancer Center, will give the talk Friday, March 9, from noon to 1 p.m. in the Iris S. and Bert L. Wolstein Research Building auditorium.

About the speaker

Reshmi Parameswaran’s lab focuses on developing novel immunotherapy methods for hematologic malignancies and cell therapy methods using natural killer cells. She also is trying to elucidate the mechanism of drug resistance in leukemia patients.

Parameswaran received her master’s degree in biochemistry from Mahatma Gandhi University, India. She moved to Israel for her doctoral studies and obtained a PhD degree in cell biology from the Weizmann Institute of Science, Israel, in 2006.

She studied the role of a cytokine Activin A in B cell development and developed cell therapy approaches for multiple myeloma using mesenchymal cells over-expressing Activin A.

Parameswaran did her post-doctoral fellowship at Children’s Hospital Los Angeles (2009-13), where she explored the role of B cell activating factor (BAFF) in pediatric acute lymphoblastic leukemia (ALL) and she was the first to identify the expression of BAFF receptor in ALL cells.

About the series

This interdisciplinary seminar series addresses cutting edge clinical, translational and basic research topics in cancer, with a focal point of the educational and inter-programmatic activities of the Case Comprehensive Cancer Center.

See more information.